Kochi M, Ushio Y (2002) Chemo-radiotherapy for malignant brain tumors. Gan To Kagaku Ryoho 29(5):669–676Kochi, M,Y. Ushio.Chemo-radiotherapy for malignant brain tumors.Gan To Kagaku Ryono. 2002Kochi, M,Y. Ushio.Chemo-radiotherapy for malignant brain tumors. Gan To Kagaku Ryono . 2002...
[18]Mathis SE,et al. Chemo-predictive assay for targeting cancer stem-like cells in patients affected by brain tumors. PLoS One. 2014 Aug 21;9(8):e105710. [19]Howard CM,et al. Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent ovarian cancer. Transl Oncol. 2020 ...
[16].Mathis SE,et al. Chemo-predictive assay for targeting cancer stem-like cells in patients affected by brain tumors. PLoS One. 2014 Aug 21;9(8):e105710. [17].Pan ST, Li ZL, He ZX, Qiu JX, Zhou SF. Molecular mecha...
Novel chemosensitivity assay for targeting cancer stem-like cells in brain tumors Cancer stem-like cells (CSLCs) in primary brain tumors can resist certain chemotherapies, thereby causing relapse of the disease. Thus, development of a test that identifies the most effective chemotherapy management off...
aChemo-Predictive Assay for Targeting Cancer Stem-Like Cells in Patients Affected by Brain Tumors. Chemo有预测性的分析用试样为瞄准巨蟹星座词根象细胞在脑瘤的影响的患者。[translate]
Scientists at the University of Rochester in New York examined the neural impact of three chemotherapeutic drugs: cisplatin, often used to treat breast, lung, and colon cancer; carmustine, used to treat brain tumors; and cytarabine, a treatment for leukemia and some lymphomas. The drugs caused ...
The first clinical trial to demonstrate the feasibility of a convection-enhanced delivery (CED) system that acts as "chemosurgery" in the brainstem could revolutionize treatment for one of the deadliest central nervous system tumors of childhood, according to researchers. ...
The entire group had an overall survival rate of 96 percent, with 98 percent of patients with favorable tumors living at least three years and 93 percent of patients with unfavorable tumors living at least three years. “This trial will lead to permanent treatment reductions in our protocol for...
tumors, the improved survival with morning chemotherapy was more pronounced. Patients with this tumor type tend to respond better to temozolomide in general. For the 56 patients with MGMT methylated tumors, average overall survival was about 25½ months for those taking the drug in the morning ...
edan1144165751over a year ago Hi, there. It doesn’t have to mean that your nephew has cancer. Tumor can also be benign. In this case no chemotherapy will be necessary. Cholesteatoma is one of the most common benign tumors of the middle ear. Antibiotics and eardrops are usually used here...